Bacopa monnieri medicinal uses pdf



 1. Jain PK, Das D, Jain P, Jain P, Jain PK. Pharmacognostic and pharmacological aspect of Bacopa monnieri - a review. Innovare J Ayurvedic Sci.
(2016) 4, 796-11. [Google Scholar]2. Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer's disease. Ann Neurosci. (2017) 24:111–22. 10.1159/000475900 [PMC free article] [PubMed] [CrossRef] [Google Scholar]3. Bhattacharya S, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity ofBacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. (2000) 14:174–9. 10.1002/(SICI)1099-1573(200005)14:3andlt;174::AID-PTR624andgt;3.0.CO;2-O [PubMed] [CrossRef] [Google Scholar]4. Kapoor R, Srivastava S, Kakkar P. Bacopa monnieri modulates antioxidant responses in brain and kidney of diabetic rats. Environ Toxicol Pharmacol. (2009) 27:62–9. 10.1016/j.etap.2008.08.007 [PubMed] [CrossRef] [Google Scholar]5. Anbarasi K, Vani G, Balakrishna K, Devi CS. Effect of bacoside A on brain antioxidant status in cigarette smoke exposed rats. Life Sci. (2006) 78:1378–84. 10.1016/j.lfs.2005.07.030 [PubMed] [CrossRef] [Google Scholar]6. Anand T, Naika M, Swamy M, Khanum F.

Antioxidant and DNA damage preventive properties of Bacopa monniera (L.) wettst. Free Rad Antioxid. (2011) 1:84–90. 10.5530/ax.2011.1.13 [CrossRef] [Google Scholar]7.
Russo A, Izzo AA, Borrelli F, Renis M, Vanella A. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytother Res. (2003) 17:870–5.

10.1002/ptr.1061 [PubMed] [CrossRef] [Google Scholar]8. Phulara SC, Shukla V, Tiwari S, Pandey R. Bacopa monnieri promotes longevity in Caenorhabditis elegans under stress conditions.
Pharmacogn Mag. (2015) 11:410. 10.4103/0973-1296.153097 [PMC free article] [PubMed] [CrossRef] [Google Scholar]9. Oyouni AAA, Saggu S, Tousson E, Mohan A, Farasani A. Mitochondrial nephrotoxicity induced by tacrolimus (FK-506) and modulatory effects of Bacopa monnieri (Farafakh) of Tabuk region. Pharmacognosy Res. (2019) 11. 10.4103/pr.pr_100_18 [CrossRef] [Google Scholar]10. Abdul Manap AS, Vijayabalan S, Madhavan P, Chia YY, Arya A, Wong EH, et al.. Bacopa monnieri, a neuroprotective lead in Alzheimer Disease: a review on its properties, mechanisms of action, and preclinical and clinical studies. Drug Target Insights.

(2019) 13:1177392819866412. 10.1177/1177392819866412 [PMC free article] [PubMed] [CrossRef] [Google Scholar]11. Bhandari P, Kumar N, Singh B, Kaul VK. Cucurbitacins from Bacopa monnieri.
Phytochemistry. (2007) 68:1248–54. 10.1016/j.phytochem.2007.03.013 [PubMed] [CrossRef] [Google Scholar]12. Chakravarty AK, Sarkar T, Nakane T, Kawahara N, Masuda K. New phenylethanoid glycosides from Bacopa monniera. Chem Pharm Bull. (2002) 50:1616–8.
10.1248/cpb.50.1616 [PubMed] [CrossRef] [Google Scholar]13. Rauf K, Subhan F, Al-Othman A, Khan I, Zarrelli A, Shah M. Preclinical profile of bacopasides from Bacopa monnieri (BM) as an emerging class of therapeutics for management of chronic pains.
Curr Med Chem. (2013) 20:1028–37. 10.2174/092986713805288897 [PubMed] [CrossRef] [Google Scholar]14. Chatterji N, Rastogi R, Dhar M. Chemical examination of Bacopa monniera Wettst: Part I-Isolation of chemical constituents. Indian J Chem. (1963) 1:212–5. [Google Scholar]15. Mathew J, Paul J, Nandhu M, Paulose C. Bacopa monnieri and Bacoside-A for ameliorating epilepsy associated behavioral deficits. Fitoterapia. (2010) 81:315–22. 10.1016/j.fitote.2009.11.005 [PubMed] [CrossRef] [Google Scholar]16. Deepak M, Amit A. The need for establishing identities of'bacoside A and B', the putative major bioactive saponins of Indian medicinal plant Bacopa monnieri. Phytomedicine. (2004) 11:264. 10.1078/0944-7113-00351 [PubMed] [CrossRef] [Google Scholar]17. Bhandari P, Sendri N, Devidas SB.

Dammarane triterpenoid glycosides in Bacopa monnieri: a review on chemical diversity and bioactivity. Phytochemistry. (2020) 172:112276. 10.1016/j.phytochem.2020.112276 [PubMed] [CrossRef] [Google Scholar]18. Kishore K, Singh M. Effect of bacosides, alcoholic extract of Bacopa monniera Linn. (brahmi), on experimental amnesia in mice. Indian J Exp Biol. (2005) 43:640–5.
[PubMed] [Google Scholar]19. Deepak M, Amit A.
'Bacoside B'—the need remains for establishing identity. Fitoterapia. (2013) 87:7–10. 10.1016/j.fitote.2013.03.011 [PubMed] [CrossRef] [Google Scholar]20. Sivaramakrishna C, Rao CV, Trimurtulu G, Vanisree M, Subbaraju GV. Triterpenoid glycosides from Bacopa monnieri. Phytochemistry. (2005) 66:2719–28.
10.1016/j.phytochem.2005.09.016 [PubMed] [CrossRef] [Google Scholar]21. Chandel R, Kulshreshtha D, Rastogi R. Bacogenin-A3: a new sapogenin from Bacopa monniera.
Phytochemistry. (1977) 16:141–3. 10.1016/0031-9422(77)83039-2 [CrossRef] [Google Scholar]22. Kulshreshtha D, Rastogi R. Bacogenin-A1: a novel dammarane triterpene sapogenin from Bacopa monniera.
Phytochemistry. (1973) 12:887–92. 10.1016/0031-9422(73)80697-1 [CrossRef] [Google Scholar]23. Kulshreshtha D, Rastogi R. Bacogenin A2: a new sapogenin from bacosides. Phytochemistry. (1974) 13:1205–6. 10.1016/0031-9422(74)80101-9 [CrossRef] [Google Scholar]24. Kulshreshtha D, Rastogi R. Identification of ebelin lactone from Bacoside A and the nature of its genuine sapogenin. Phytochemistry. (1973) 12:2074–6. 10.1016/S0031-9422(00)91552-8 [CrossRef] [Google Scholar]25. Rastogi S, Pal R, Kulshreshtha DK. Bacoside A3? A triterpenoid saponin from Bacopa monniera. Phytochemistry.
(1994) 36:133–7. 10.1016/S0031-9422(00)97026-2 [PubMed] [CrossRef] [Google Scholar]26. Chakravarty AK, Garai S, Masuda K, Nakane T, Kawahara N. Bacopasides III—V: three new triterpenoid glycosides from Bacopa monniera. Chem Pharma Bull. (2003) 51:215–7. 10.1248/cpb.51.215 [PubMed] [CrossRef] [Google Scholar]27. Chakravarty AK, Sarkar T, Masuda K, Shiojima K, Nakane T, Kawahara N. Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monniera. Phytochemistry.
(2001) 58:553–6. 10.1016/S0031-9422(01)00275-8 [PubMed] [CrossRef] [Google Scholar]28. Garai S, Mahato SB, Ohtani K, Yamasaki K. Dammarane-type triterpenoid saponins from Bacopa monniera. Phytochemistry. (1996) 42:815–20. 10.1016/0031-9422(95)00936-1 [PubMed] [CrossRef] [Google Scholar]29. Garai S, Mahato SB, Ohtani K, Yamasaki K. Bacopasaponin DA pseudojujubogenin glycoside from Bacopa monniera.
Phytochemistry. (1996) 43:447–9. 10.1016/0031-9422(96)00250-6 [PubMed] [CrossRef] [Google Scholar]30. Mahato SB, Garai S, Chakravarty AK. Bacopasaponins E and F: two jujubogenin bisdesmosides from Bacopa monniera. Phytochemistry. (2000) 53:711–4. 10.1016/S0031-9422(99)00384-2 [PubMed] [CrossRef] [Google Scholar]31. Huangteerakul C, Aung HM, Thosapornvichai T, Duangkaew M, Jensen AN, Sukrong S, et al.. Chemical-genetic interactions of Bacopa monnieri constituents in cells deficient for the DNA repair endonuclease RAD1 appear linked to vacuolar disruption. Molecules. (2021) 26:1207. 10.3390/molecules26051207 [PMC free article] [PubMed] [CrossRef] [Google Scholar]32. Sinha J, Raay B, Das N, Medda S, Garai S, Mahato S, et al.. Bacopasaponin C: critical evaluation of anti-leishmanial properties in various delivery modes.
Drug Deliv. (2002) 9:55–62.
10.1080/107175402753413181 [PubMed] [CrossRef] [Google Scholar]33. Miro M. Cucurbitacins and their pharmacological effects. Phytother Res. (1995) 9:159–68. 10.1002/ptr.2650090302 [CrossRef] [Google Scholar]34. Chowdhury AR, Mandal S, Mittra B, Sharma S, Mukhopadhyay S, Majumder HK. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monitor. (2002) 8:BR254–60. 10.12659/MSM.937927 [PubMed] [CrossRef] [Google Scholar]35. Ghosh T, Maity TK, Singh J. Antihyperglycemic activity of bacosine, a triterpene from Bacopa monnieri, in alloxan-induced diabetic rats. Planta Med. (2011) 77:804–8. 10.1055/s-0030-1250600 [PubMed] [CrossRef] [Google Scholar]36. Palethorpe HM, Smith E, Tomita Y, Nakhjavani M, Yool AJ, Price TJ, et al.. Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell lines. Molecules. (2019) 24:3539. 10.3390/molecules24193539 [PMC free article] [PubMed] [CrossRef] [Google Scholar]37. Pei JV, Kourghi M, De Ieso ML, Campbell EM, Dorward HS, Hardingham JE, et al.. Differential inhibition of water and ion channel activities of mammalian aquaporin-1 by two structurally related bacopaside compounds derived from the medicinal plant bacopa monnieri. Mol Pharmacol. (2016) 90:496–507. 10.1124/mol.116.105882 [PubMed] [CrossRef] [Google Scholar]38. Smith E, Palethorpe HM, Tomita Y, Pei JV, Townsend AR, Price TJ, et al.. The purified extract from the medicinal plant Bacopa monnieri, bacopaside II, inhibits growth of colon cancer cells in vitro by inducing cell cycle arrest and apoptosis. Cells. (2018) 7:81. 10.3390/cells7070081 [PMC free article] [PubMed] [CrossRef] [Google Scholar]39.
Puoti C. New insights on hepatocellular carcinoma: epidemiology and clinical aspects. Hepatoma Res. (2018) 4:57.
10.20517/2394-5079.2018.67 [CrossRef] [Google Scholar]40. Garg A, Kumar A, Nair A, Reddy A. Elemental analysis of brahmi (Bacopa monnieri) extracts by neutron activation and its bioassay for antioxidant, radio protective and anti-lipid peroxidation activity. J Radioanal Nuclear Chem. (2009) 281:53–8. 10.1007/s10967-009-0081-z [CrossRef] [Google Scholar]41. Ghosh T, Maity T, Bose A, Dash GK, Das M.
A study on antimicrobial activity of Bacopa monnieri Linn. aerial parts. J Nat Remed. (2006) 6:170–3. [Google Scholar]42. Xu Z, Shi M, Tian Y, Zhao P, Niu Y, Liao M. Dirhamnolipid produced by the pathogenic fungus Colletotrichum gloeosporioides BWH-1 and its herbicidal activity. Molecules. (2019) 24:2969. 10.3390/molecules24162969 [PMC free article] [PubMed] [CrossRef] [Google Scholar]43. Janani P, Sivakumari K, Geetha A, Ravisankar B, Parthasarathy C. Chemopreventive effect of bacoside A on N-nitrosodiethylamine-induced hepatocarcinogenesis in rats. J Cancer Res Clin Oncol. (2010) 136:759–70. 10.1007/s00432-009-0715-0 [PubMed] [CrossRef] [Google Scholar]44. Janani P, Sivakumari K, Geetha A, Yuvaraj S, Parthasarathy C.
Bacoside A downregulates matrix metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma. Cell Biochem Funct. (2010) 28:164–9. 10.1002/cbf.1638 [PubMed] [CrossRef] [Google Scholar]45. Menon BR, Rathi M, Thirumoorthi L, Gopalakrishnan V. Potential effect of Bacopa monnieri on nitrobenzene induced liver damage in rats. Indian J Clin Biochem. (2010) 25:401–4. 10.1007/s12291-010-0048-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]46. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al.. Radiotherapy for glioblastoma in the elderly. N Engl J Med. (2007) 356:1527–35. 10.1056/NEJMoa065901 [PubMed] [CrossRef] [Google Scholar]47.

Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. (2009) 29:5171–84. [PubMed] [Google Scholar]48. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, et al.. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells. (2010) 28:1019–29. 10.1002/stem.429 [PMC free article] [PubMed] [CrossRef] [Google Scholar]49. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, et al.. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. (2007) 106:417–27. 10.3171/jns.2007.106.3.417 [PubMed] [CrossRef] [Google Scholar]50. Westphal M, Maire CL, Lamszus K. EGFR as a target for glioblastoma treatment: an unfulfilled promise. CNS Drugs. (2017) 31:723–35. 10.1007/s40263-017-0456-6 [PMC free article] [PubMed] [CrossRef] [Google Scholar]51. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget.

(2011) 2:646. 10.18632/oncotarget.322 [PMC free article] [PubMed] [CrossRef] [Google Scholar]52. Abbas M, Kausar S, Cui H. Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations.

Clin Transl Oncol. (2020) 22:963–77.

10.1007/s12094-019-02227-3 [PubMed] [CrossRef] [Google Scholar]53. Mishra R, Kaur G. Aqueous ethanolic extract of Tinospora cordifolia as a potential candidate for differentiation based therapy of glioblastomas. PLoS ONE. (2013) 8:e78764. 10.1371/journal.pone.0078764 [PMC free article] [PubMed] [CrossRef] [Google Scholar]54. Racoma IO, Meisen WH, Wang Q-E, Kaur B, Wani AA. Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS ONE. (2013) 8:e72882. 10.1371/journal.pone.0072882 [PMC free article] [PubMed] [CrossRef] [Google Scholar]55.

Tavana E, Mollazadeh H, Mohtashami E, Modaresi SMS, Hosseini A, Sabri H, et al..

Quercetin: a promising phytochemical for the treatment of glioblastoma multiforme. BioFactors. (2020) 46:356–66. 10.1002/biof.1605 [PubMed] [CrossRef] [Google Scholar]56. John S, Sivakumar K, Mishra R. Bacoside A induces tumor cell death in human glioblastoma cell lines through catastrophic macropinocytosis. Front Mol Neurosci. (2017) 10:171. 10.3389/fnmol.2017.00171 [PMC free article] [PubMed] [CrossRef] [Google Scholar]57. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. (2015) 66:49–63. 10.1146/annurev-med-011514-023121 [PMC free article] [PubMed] [CrossRef] [Google Scholar]58. Łojewski M, Pomierny B, Muszyńska B, Krzyzanowska W, Budziszewska B, Szewczyk A.

Protective effects of Bacopa monnieri on hydrogen peroxide and staurosporine: induced damage of human neuroblastoma SH-SY5Y cells. Planta Med. (2016) 82:205–10. 10.1055/s-0035-1558166 [PubMed] [CrossRef] [Google Scholar]59. Petcharat K, Singh M, Ingkaninan K, Attarat J, Yasothornsrikul S. Bacopa monnieri protects SH-SY5Y cells against tert-Butyl hydroperoxide-induced cell death via the ERK and PI3K pathways. Siriraj Med J. (2015) 67:20–6. [PMC free article] [PubMed] [Google Scholar]60. Atlas D.

International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; (2015). [Google Scholar]61. Al-Attar AM, Alsalmi FA. Influence of olive leaves extract on hepatorenal injury in streptozotocin diabetic rats. Saudi J Biol Sci. (2019) 26:1865–74. 10.1016/j.sjbs.2017.02.005 [PMC free article] [PubMed] [CrossRef] [Google Scholar]62. Edwin J, Balakrishnan JS, Chandra JD. Diabetes and herbal medicines. Iran J Pharmacol Therapeut.

(2008) 97–106. [Google Scholar]63. Kooti W, Farokhipour M, Asadzadeh Z, Ashtary-Larky D, Asadi-Samani M.

The role of medicinal plants in the treatment of diabetes: a systematic review. Electron Physician. (2016) 8:1832. 10.19082/1832 [PMC free article] [PubMed] [CrossRef] [Google Scholar]64.

Rao MU, Sreenivasulu M, Chengaiah B, Reddy KJ, Chetty CM. Herbal medicines for diabetes mellitus: a review. Int J PharmTech Res. (2010) 2:1883–92. [Google Scholar]65. Ghosh T, Sengupta P, Dash D, Bose A. Antidiabetic and in vivo antioxidant activity of ethanolic extract of Bacopa monnieri Linn. aerial parts: a possible mechanism of action. Iran J Pharm Res (IJPR). (2008) 7, 61–8. [Google Scholar]66. Kishore L, Kaur N, Singh R. Renoprotective effect of Bacopa monnieri via inhibition of advanced glycation end products and oxidative stress in STZ-nicotinamide-induced diabetic nephropathy. Ren Fail. (2016) 38:1528–44.

10.1080/0886022X.2016.1227920 [PubMed] [CrossRef] [Google Scholar]67. Pandey SP, Singh HK, Prasad S. Alterations in hippocampal oxidative stress, expression of AMPA receptor GluR2 subunit and associated spatial memory loss by Bacopa monnieri extract (CDRI-08) in streptozotocin-induced diabetes mellitus type 2 mice.

PLoS ONE. (2015) 10:e0131862. 10.1371/journal.pone.0131862 [PMC free article] [PubMed] [CrossRef] [Google Scholar]68. Hosamani R. The efficacy of Bacopa monnieri extract in modulating Parkinson's disease. In: Genetics, Neurology, Behavior, and Diet in Parkinson's Disease. (2020). Cambridge, MA: Elsevier. p. 609–24. 10.1016/B978-0-12-815950-7.00039-4 [CrossRef] [Google Scholar]69. Singh B, Pandey S, Rumman M, Mahdi AA. Neuroprotective effects of Bacopa monnieri in Parkinson's disease model. Metab Brain Dis.

(2020) 35:517–25. 10.1007/s11011-019-00526-w [PubMed] [CrossRef] [Google Scholar]70. Jadiya P, Khan A, Sammi SR, Kaur S, Mir SS, Nazir A. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Biochem Biophys Res Commun. (2011) 413:605–10. 10.1016/j.bbrc.2011.09.010 [PubMed] [CrossRef] [Google Scholar]71. Singh B, Pandey S, Yadav SK, Verma R, Singh SP, Mahdi AA. Role of ethanolic extract of Bacopa monnieri against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) induced mice model via inhibition of apoptotic pathways of dopaminergic neurons. Brain Res Bull. (2017) 135:120–8. 10.1016/j.brainresbull.2017.10.007 [PubMed] [CrossRef] [Google Scholar]72. Siddique YH, Mujtaba SF, Faisal M, Jyoti S, Naz F. The effect of Bacopa monnieri leaf extract on dietary supplementation in transgenic Drosophila model of Parkinson's disease. Eur J Integr Med. (2014) 6:571–80.

10.1016/j.eujim.2014.05.007 [PMC free article] [PubMed] [CrossRef] [Google Scholar]73. Naqvi AAT, Hasan GM, Hassan MI. Targeting tau hyperphosphorylation via kinase inhibition: strategy to address Alzheimer's disease. Curr Top Med Chem. (2020) 20:1059–73. 10.2174/1568026620666200106125910 [PubMed] [CrossRef] [Google Scholar]74.

Naqvi AAT, Jairajpuri DS, Noman OMA, Hussain A, Islam A, Ahmad F, et al.. Evaluation of pyrazolopyrimidine derivatives as microtubule affinity regulating kinase 4 inhibitors: towards therapeutic management of Alzheimer's disease. J Biomol Struct Dyn. (2020) 38:3892–907. 10.1080/07391102.2019.1666745 [PubMed] [CrossRef] [Google Scholar]75.

Shamsi A, Mohammad T, Anwar S, Alajmi MF, Hussain A, Hassan MI, et al.. Probing the interaction of Rivastigmine Tartrate, an important Alzheimer's drug, with serum albumin: attempting treatment of Alzheimer's disease. Int J Biol Macromol. (2020) 148:533–42. 10.1016/j.ijbiomac.2020.01.134 [PubMed] [CrossRef] [Google Scholar]76. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's disease: past, present, and future.

J Int Neuropsychol Soc. (2017) 23:818–31. 10.1017/S135561771700100X [PMC free article] [PubMed] [CrossRef] [Google Scholar]77. Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci Ther. (2011) 17:514–24. 10.1111/j.1755-5949.2010.00177.x [PMC free article] [PubMed] [CrossRef] [Google Scholar]78. Medina M, Avila J. New perspectives on the role of tau in Alzheimer's disease. Implic Ther Biochem Pharmacol. (2014) 88:540–7. 10.1016/j.bcp.2014.01.013 [PubMed] [CrossRef] [Google Scholar]79. Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV. Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Phytother Res. (2007) 21:965–9. 10.1002/ptr.2195 [PubMed] [CrossRef] [Google Scholar]80.

Ssingh H, Rastogi R, Srimal R, Dhawan B. Effect of bacosides A and B on avoidance response in rats. Phytother Res.

(1988) 2:70–5. 10.1002/ptr.2650020205 [CrossRef] [Google Scholar]81. Das TK, Hamid M, Das T, Shad KF. Potential of Glyco-withanolides from Withania Somnifera (Ashwagandha) as therapeutic agents for the treatment of Alzheimer's disease.

World J Pharm Res.

(2015) 4:16–38. [Google Scholar]82.

Esfandiari E, Ghanadian M, Rashidi B, Mokhtarian A, Vatankhah AM. The effects of Acorus calamus L. in preventing memory loss, anxiety, and oxidative stress on lipopolysaccharide-induced neuroinflammation rat models.

Int J Prev Med. (2018) 9:85. 10.4103/ijpvm.IJPVM_75_18 [PMC free article] [PubMed] [CrossRef] [Google Scholar]83.

Habtemariam S. The therapeutic potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer's disease Evid Based Complement Altern Med. (2016) 2016:2680409. 10.1155/2016/2680409 [PMC free article] [PubMed] [CrossRef] [Google Scholar]84. Kim H-J, Jung S-W, Kim S-Y, Cho I-H, Kim H-C, Rhim H, et al.. Panax ginseng as an adjuvant treatment for Alzheimer's disease. J Ginseng Res. (2018) 42:401–11. 10.1016/j.jgr.2017.12.008 [PMC free article] [PubMed] [CrossRef] [Google Scholar]85. Liao Z, Cheng L, Li X, Zhang M, Wang S, Huo R. Meta-analysis of Ginkgo biloba preparation for the treatment of Alzheimer's disease. Clin Neuropharmacol. (2020) 43:93–9. 10.1097/WNF.0000000000000394 [PubMed] [CrossRef] [Google Scholar]86.

Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol. (2010) 127:26–31. 10.1016/j.jep.2009.09.056 [PubMed] [CrossRef] [Google Scholar]87. Holcomb LA, Dhanasekaran M, Hitt AR, Young KA, Riggs M, Manyam BV. Bacopa monniera extract reduces amyloid levels in PSAPP mice. J Alzheimers Dis.

(2006) 9:243–51. 10.3233/JAD-2006-9303 [PubMed] [CrossRef] [Google Scholar]88. Mathew M, Subramanian S. Evaluation of the anti-amyloidogenic potential of nootropic herbal extracts in vitro. Int J Pharm Sci Res. (2012) 3:4276–80. [Google Scholar]89. Roy S, Chakravarty S, Talukdar P, Talapatra SN. Identification of bioactive compounds present in Bacopa monnieri Linn. against caspase-3 and Tau Protein Kinase I to prevent alzheimer's disease: an in silico study. Pharma Innov. J. (2019) 8:855–61. [Google Scholar]90. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol.

(2008) 120:112–7. 10.1016/j.jep.2008.07.039 [PubMed] [CrossRef] [Google Scholar]91. Pandareesh M, Anand T. Neuromodulatory propensity of Bacopa monniera against scopolamine-induced cytotoxicity in PC12 cells via down-regulation of AChE and up-regulation of BDNF and muscarnic-1 receptor expression. Cell Mol Neurobiol. (2013) 33:875–84. 10.1007/s10571-013-9952-5 [PubMed] [CrossRef] [Google Scholar]92. Malishev R, Shaham-Niv S, Nandi S, Kolusheva S, Gazit E, Jelinek R. Bacoside-A, an Indian traditional-medicine substance, inhibits β-amyloid cytotoxicity, fibrillation, and membrane interactions. ACS Chem Neurosci. (2017) 8:884–91. 10.1021/acschemneuro.6b00438 [PubMed] [CrossRef] [Google Scholar]93. Bhatia G, Dhuna V, Dhuna K, Kaur M, Singh J. Bacopa monnieri extracts prevent hydrogen peroxide-induced oxidative damage in a cellular model of neuroblastoma IMR32 cells. Chin J Nat Med.

(2017) 15:834–46. 10.1016/S1875-5364(18)30017-7 [PubMed] [CrossRef] [Google Scholar]94. Fassl A, Tagscherer K, Richter J, Diaz MB, Llaguno SA, Campos B, et al.. Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene. (2012) 31:4698–708. 10.1038/onc.2011.615 [PubMed] [CrossRef] [Google Scholar]95. Aithal MG, Rajeswari N. Bacoside A induced sub-G0 arrest and early apoptosis in human glioblastoma cell line U-87 MG through notch signaling pathway. Brain Tumor Res Treat. (2019) 7:25–32. 10.14791/btrt.2019.7.e21 [PMC free article] [PubMed] [CrossRef] [Google Scholar]96. Kunte KB, Kuna Y. Neuroprotective effect of Bacopa monniera on memory deficits and ATPase system in Alzheimer's disease (AD) induced mice. J Sci Innov Res. (2013) 2:719–35. [Google Scholar]97. Cheng Y-J, Lin C-H, Lane H-Y. Involvement of cholinergic, adrenergic, and glutamatergic network modulation with cognitive dysfunction in Alzheimer's disease.

Int J Mol Sci.

(2021) 22:2283. 10.3390/ijms22052283 [PMC free article] [PubMed] [CrossRef] [Google Scholar]98. Schaeffer EL, Gattaz WF. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A 2 enzyme. Psychopharmacology. (2008) 198:1–27. 10.1007/s00213-008-1092-0 [PubMed] [CrossRef] [Google Scholar]99. Le XT, Pham HTN, Do PT, Fujiwara H, Tanaka K, Li F, et al..

Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems. Neurochem Res. (2013) 38:2201–15. 10.1007/s11064-013-1129-6 [PubMed] [CrossRef] [Google Scholar]100. Kishore D, Babu RS, Begum A, Noor A, Farheen S, Kauser SM, et al.. Evaluation of nootropic activity of two marketed drugs of Bacopa monnieri in scopolamine induced amnesic models. Indian J Res Pharmacy Biotechnol.

(2018) 6:84–90. [Google Scholar]101. Piyabhan P, Tingpej P, Duansak N. Effect of pre-and post-treatment with Bacopa monnieri (Brahmi) on phencyclidine-induced disruptions in object recognition memory and cerebral calbindin, parvalbumin, and calretinin immunoreactivity in rats. Neuropsychiatr Dis Treat.

(2019) 15:1103. 10.2147/NDT.S193222 [PMC free article] [PubMed] [CrossRef] [Google Scholar]102. Singh B, Pandey S, Rumman M, Kumar S, Kushwaha PP, Verma R, et al.. Neuroprotective and neurorescue mode of action of Bacopa monnieri (L.) Wettst in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease: an in silico and in vivo study. Front Pharmacol. (2021) 12:169. 10.3389/fphar.2021.616413 [PMC free article] [PubMed] [CrossRef] [Google Scholar]103. Stough C, Lloyd J, Clarke J, Downey L, Hutchison C, Rodgers T, et al.. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. (2001) 156:481–4. 10.1007/s002130100815 [PubMed] [CrossRef] [Google Scholar]104. Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, et al.. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res.

(2008) 22:1629–34. 10.1002/ptr.2537 [PubMed] [CrossRef] [Google Scholar]105. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory.

Neuropsychopharmacology. (2002) 27:279–81. 10.1016/S0893-133X(01)00419-5 [PubMed] [CrossRef] [Google Scholar]106. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complem Med. (2010) 16:753–9. 10.1089/acm.2009.0342 [PubMed] [CrossRef] [Google Scholar]107. Peth-Nui T, Wattanathorn J, Muchimapura S, Tong-Un T, Piyavhatkul N, Rangseekajee P, et al..

Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evid Based Complem Altern Med. (2012) 2012:606424. 10.1155/2012/606424 [PMC free article] [PubMed] [CrossRef] [Google Scholar]108. Benson S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. (2014) 28:551–9. 10.1002/ptr.5029 [PubMed] [CrossRef] [Google Scholar]109. Kean JD, Kaufman J, Lomas J, Goh A, White D, Simpson D, et al.. A randomized controlled trial investigating the effects of a special extract of Bacopa monnieri (CDRI 08) on hyperactivity and inattention in male children and adolescents: BACHI study protocol (ANZCTRN12612000827831). Nutrients. (2015) 7:9931–45. 10.3390/nu7125507 [PMC free article] [PubMed] [CrossRef] [Google Scholar]110. Kumar N, Abichandani L, Thawani V, Gharpure K, Naidu M, Venkat Ramana G. Efficacy of standardized extract of Bacopa monnieri (Bacognize®) on cognitive functions of medical students: a six-week, randomized placebo-controlled trial.

Evid Based Complem Altern Med. (2016) 2016:4103423. 10.1155/2016/4103423 [PMC free article] [PubMed] [CrossRef] [Google Scholar]111. Mishra M, Mishra AK, Mishra U. Brahmi (Bacopa monnieri Linn.) in the treatment of dementias–a pilot study. Fut Healthc J. (2019) 6:69. 10.7861/futurehosp.6-1-s69 [PMC free article] [PubMed] [CrossRef] [Google Scholar]112. Micheli L, Spitoni S, Di Cesare Mannelli L, Bilia AR, Ghelardini C, Pallanti S. Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. Phytother Res. (2020) 34:2331–40. 10.1002/ptr.6684 [PubMed] [CrossRef] [Google Scholar]113. Sanzini E, Badea M, Dos Santos A, Restani P, Sievers H. Quality control of plant food supplements. Food Funct. (2011) 2:740–6. 10.1039/c1fo10112a [PubMed] [CrossRef] [Google Scholar]114. George P. Concerns regarding the safety and toxicity of medicinal plants-An overview. J Appl Pharm Sci. (2011) 1:40–4.

[Google Scholar]115. Balaji B, Kumar EP, Kumar A. Evaluation of standardized Bacopa monniera extract in sodium fluoride-induced behavioural, biochemical, and histopathological alterations in mice. Toxicol Ind Health. (2015) 31:18–30. 10.1177/0748233712468018 [PubMed] [CrossRef] [Google Scholar]116.

Singh D, Arya P, Koolwal N, Singh V, Saxena R, Sharma M, et al.. Protective role of Bacopa monniera L. against hepatic oxidative stress in wistar albino rats. J Pharmacogn Phytochem. (2015) 4:233. [Google Scholar]117. Shahid M, Subhan F, Ullah I, Ali G, Alam J, Shah R. Beneficial effects of Bacopa monnieri extract on opioid induced toxicity. Heliyon. (2016) 2:e00068. 10.1016/j.heliyon.2016.e00068 [PMC free article] [PubMed] [CrossRef] [Google Scholar]118. Sumathi T, Devaraj SN. Effect of Bacopa monniera on liver and kidney toxicity in chronic use of opioids. Phytomedicine. (2009) 16:897–903. 10.1016/j.phymed.2009.03.005 [PubMed] [CrossRef] [Google Scholar]119. Srivastav S, Fatima M, Mondal AC.

Bacopa monnieri alleviates paraquat induced toxicity in Drosophila by inhibiting jnk mediated apoptosis through improved mitochondrial function and redox stabilization. Neurochem Int.

(2018) 121:98–107. 10.1016/j.neuint.2018.10.001 [PubMed] [CrossRef] [Google Scholar]120. Jyoti A, Sethi P, Sharma D. Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. J Ethnopharmacol. (2007) 111:56–62. 10.1016/j.jep.2006.10.037 [PubMed] [CrossRef] [Google Scholar]121. Velaga MK, Basuri CK, Robinson Taylor KS, Yallapragada PR, Rajanna S, Rajanna B. Ameliorative effects of Bacopa monniera on lead-induced oxidative stress in different regions of rat brain. Drug Chem Toxicol. (2014) 37:357–64. 10.3109/01480545.2013.866137 [PubMed] [CrossRef] [Google Scholar]122. Ayyathan DM, Chandrasekaran R, Thiagarajan K. Neuroprotective effect of Brahmi, an ayurvedic drug against oxidative stress induced by methyl mercury toxicity in rat brain mitochondrial-enriched fractions. Nat Prod Res. (2015) 29:1046–51. 10.1080/14786419.2014.968153 [PubMed] [CrossRef] [Google Scholar]123. Dwivedi S, Nagarajan R, Hanif K, Siddiqui HH, Nath C, Shukla R. (2013). Standardized extract of Bacopa monniera attenuates okadaic acid induced memory dysfunction in rats: effect on Nrf2 pathway. Evid Based Complem Altern Med. (2013) 2013:294501.

10.1155/2013/294501 [PMC free article] [PubMed] [CrossRef] [Google Scholar]124. Pham HTN, Phan SV, Tran HN, Phi XT, Le XT, Nguyen KM, et al.. Bacopa monnieri (L.) ameliorates cognitive deficits caused in a trimethyltin-induced neurotoxicity model mice. Biolo Pharm Bull. (2019) 42:1384–93. 10.1248/bpb.b19-00288 [PubMed] [CrossRef] [Google Scholar]125. Brimson JM, Prasanth MI, Plaingam W, Tencomnao T. Bacopa monnieri (L.) wettst. Extract protects against glutamate toxicity and increases the longevity of Caenorhabditis elegans. J Trad Complemen Med.

(2020) 10:460–70. 10.1016/j.jtcme.2019.10.001 [PMC free article] [PubMed] [CrossRef] [Google Scholar]126. Sireeratawong S, Jaijoy K, Khonsung P, Lertprasertsuk N, Ingkaninan K. Acute and chronic toxicities of Bacopa monnieri extract in Sprague-Dawley rats. BMC Complement Altern Med. (2016) 16:249. 10.1186/s12906-016-1236-4 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Page 2PMC full text:Summary of in vitro and in vivo studies.S. No. Cell line/Model Cytotoxicity induced/culture prepared Protein/pathway involved Dosage and effect of BME treatment Mechanism of action References In vitro study1.Primary cortical cultured neuronsAβ25–35 (50 μM)β-amyloid100 g/mL protect neurons from beta-amyloid-induced cell deathInhibitory effect on amyloid peptide-activated intracellular AChE activity.(90)2.PC12Scopolamine (3 μg/ml)BDNF, MUS-1 and AChE100 μg/mL of BME ameliorated the mitochondria and plasma membrane damageDown-regulation of AChE. Up-regulation of BDNF receptor expression. Up-regulation of muscarnic-1 receptor expression.(91)3.SH-SY5YAβ42 (10 μM)β-amyloid50 μM of Bacoside-A inhibits βamyloid cytotoxicity, fibrillation, and membrane interactions.Prevent self-assembly of oligomers.(92)4.IMR32H_2O_2 (250 $\mu mol \cdot L^{-1}$)NF200, HSP70, and mortalinBelow 100 $\mu g \cdot mL^{-1}$ prevent oxidative damageBy downregulating the NF200 expression of IMR32, HSP70, and mortalin cells.(93)5.U-87 MGU-87 MG in DMEM supplemented with 10% FBSNotch signaling pathway80 μg/mL of Bacoside A Induced Sub-G0 Arrest and Early ApoptosisInduced cell death and apoptosis.(95)In vivo study6. Mus musculus D-Galactose and Sodium nitriteATPase system100 mg/kg body weight of BMEInhibition of calcium-ion influx into cell membranes.(96)7.Male ddY miceOBX miceGlutamatergic and Cholinergic systems50 mg/kg of BMEFacilitation cholinergic neurotransmission. Modulation Hippocampal synaptic plasticity. Mobilization of intracellular Ca^{2+} ion.(99)8.Albino micescopolamine (40 mg/kg i.p.)Cholinergic system100 mg/kg of BMEInhibition of acetylcholinesterase. Activation of choline acetyltransferase.(100)9.Male Wistar ratsPCP (2 mg/kg)Calcium-binding proteins (CB, PV, CR) localize mainly in GABAergic neurons.225 mg of BMEBy restoration of GABAergic neurons.(101)10.Swiss Albino miceMPTP (30 mg/kg BW)Dopamine degradation pathway40 mg/kg BWBy maintain dopamine concentrations either by increasing dopamine synthesis or by inhibiting dopamine degradation.(102)